Company Filing History:
Years Active: 2013-2017
Title: Keiko Esaki: Innovator in Cancer Therapeutics
Introduction
Keiko Esaki is a prominent inventor based in Shizuoka, Japan. She has made significant contributions to the field of cancer therapeutics, particularly through her work on anti-Epiregulin antibodies. With a total of 3 patents to her name, her innovations are paving the way for new treatments in oncology.
Latest Patents
Among her latest patents is the development of a humanized anti-Epiregulin antibody, which serves as a cancer therapeutic agent. This invention showcases the ability to produce anti-Epiregulin antibodies that exhibit cross-species reactivity between cynomolgus monkeys and humans. Additionally, these antibodies have been engineered to suppress chemical degradation, lower isoelectric points, and increase thermal denaturation midpoint temperatures. The antibodies also demonstrate reduced aggregation through specific amino acid residue substitutions in the variable-region sequences of the humanized EP27 antibody. This innovation is crucial as it inhibits the growth of cancer cells by exhibiting cytotoxic and neutralizing activities against human Epiregulin-expressing cancer cells. Another notable patent involves nucleic acids encoding anti-NR10 antibodies, which possess effective neutralizing activity against NR10 and are useful in treating or preventing inflammatory diseases.
Career Highlights
Keiko Esaki is currently associated with Chugai Seiyaku Kabushiki Kaisha, where she continues her groundbreaking research. Her work has garnered attention in the scientific community, contributing to advancements in therapeutic strategies for cancer treatment.
Collaborations
Throughout her career, she has collaborated with notable colleagues such as Taichi Kuramochi and Hiroyuki Tsunoda. These partnerships have further enhanced her research and development efforts in the field.
Conclusion
Keiko Esaki's innovative work in the development of anti-Epiregulin antibodies and anti-NR10 antibodies highlights her significant impact on cancer therapeutics. Her contributions are vital for advancing treatment options and improving patient outcomes in oncology.